KANDLELIT-001

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Sep 15, 2023 → Oct 25, 2026

Cited window

Sep 15, 2023 → Oct 25, 2026

Retrieved

Oct 31, 2026

Title

A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors

Registry

NCT05067283

Study IDs

1084-001 · MK-1084-001 (MSD) · jRCT2041220034 (jRCT) · 2022-501563-40-00 (EU CT) · U1111-1281-2482 (UTN)

Sponsor

Merck Sharp & Dohme LLC

Design

Phase 1 · Interventional, non randomized, parallel

Status

Recruiting

Enrollment

830 estimated

Registered

2021-10-05

Start

2021-12-17 actual

Primary completion

2030-02-25 estimated

Primary endpoint

Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)

Interventions

8 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –45 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –Repeated posts, institutional presentation coverage, reshares and closely matching interview versions are not independent HCP assessments.
• –The reported cohort results differ in population, prior treatment, biomarker group, regimen and presentation. Common analysis dates are not established, and the figures cannot support a simple cross-cohort efficacy ranking.
• –CRC triplet safety is reported differently: 25% grade ≥3 treatment-related adverse events in a speaker's account versus 15% grade 3+ adverse events in another speaker's. The event definitions and numerical difference remain unresolved.
• –No full protocol or results publication is available in the material reviewed. Regulatory information is incomplete and does not establish the trial-information video's assertion that all constituent drugs are approved.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Post and video publication dates are not necessarily presentation dates. Differences between reports do not establish a change of mind or disagreement across settings.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "KANDLELIT-001" (NCT05067283), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "kandlelit-001-05067283". If you cannot make requests, read https://www.erudio.com/reports/kandlelit-001-nct05067283.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT05067283", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct05067283 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/kandlelit-001-nct05067283.json
curl https://www.erudio.com/reports/kandlelit-001-nct05067283.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "kandlelit-001-05067283" })